Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T17924 |
(S,R,S)-AHPC-PEG2-NH2 hydrochloride
VH032-PEG2-NH2 hydrochloride,VHL Ligand-Linker Conjugates 3 hydrochloride,E3 ligase Ligand-Linker Conjugates 6 |
Others; E3 Ligase Ligand-Linker Conjugate | Others; PROTAC |
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 6) 包含基于 (S,R,S)-AHPC 的 VHL 配体和 2 个单元 PEG linker,是一种合成的 E3 连接酶配体-linker 偶联物,可用于 PROTAC 的合成分子。 | |||
T18600 |
VH032 thiol
VHL ligand 6 |
Others | Others |
VH032 thiol (VHL ligand 6) is a VHL ligand that interacts with pan-BET inhibitor JQ1 through a linker to create a PROTAC[1] compound. | |||
T13671L |
(S,R,S)-AHPC-Me dihydrochloride
VHL ligand 2 dihydrochloride,E3 ligase Ligand 1 dihydrochloride,(S,R,S)-AHPC-Me dihydrochloride (1948273-02-6 free base) |
Others | Others |
(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound utilized in the synthesis of ARV-771. ARV-771, a BET PROTAC degrader relying on von Hippel-Landau (VHL) E3 ligase, demonstrates potent degradation of BET protein in castration-resistant prostate cancer (CRPC) cells, with a DC50 of less than 1 nM. This compound serves as the VHL ligand, specifically the (S,R,S)-AHPC-based VHL ligand, that facilitates the recruitment of von Hippel-Lindau (VHL) prote... | |||
T17913 |
(S,R,S)-AHPC-PEG2-N3
VHL Ligand-Linker Conjugates 6,VH032-PEG2-N3,E3 ligase Ligand-Linker Conjugates 13 |
Others; Ligand for E3 Ligase | Others; PROTAC |
(S,R,S)-AHPC-PEG2-N3 (VHL Ligand-Linker Conjugates 6) 包含基于 (S,R,S)-AHPC 的 VHL 配体和 2 个单元 PEG linker,是一种合成的 E3 连接酶配体-linker 偶联物。 | |||
T17925 |
(S,R,S)-AHPC-PEG2-NH2
VH032-PEG2-NH2,VHL Ligand-Linker Conjugates 3,E3 ligase Ligand-Linker Conjugates 6 Free Base |
Others; E3 Ligase Ligand-Linker Conjugate | Others; PROTAC |
(S,R,S)-AHPC-PEG2-NH2 (VHL Ligand-Linker Conjugates 3) 包含基于 (S,R,S)-AHPC 的 VHL 配体和 2 个单元 PEG linker,是一种合成的 E3 连接酶配体-linker 偶联物。可用于 PROTAC 的合成分子。 | |||
T17926 |
(S,R,S)-AHPC-PEG6-C4-Cl
VHL Ligand-Linker Conjugates 10,E3 ligase Ligand-Linker Conjugates 9,VH032-PEG6-C4-Cl |
Others | Others |
(S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1]. | |||
T17911 |
(S,R,S)-AHPC-C6-PEG3-C4-Cl
VH032-C6-PEG3-C4-Cl,VHL Ligand-Linker Conjugates 12,E3 ligase Ligand-Linker Conjugates 8 |
Others | Others |
(S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1]. | |||
T17350 |
ACBI1
|
Apoptosis; Epigenetic Reader Domain; PROTACs | Apoptosis; Chromatin/Epigenetic; PROTAC |
ACBI1 是一种基于PROTAC 技术的 BAF ATPase 亚基SMARCA2和SMARCA4降解剂,也是 PBAF 成员PBRM1的降解剂。它由一个 bromodomain 配体、linker 和 E3 泛素连接酶von Hippel-Lindau 构成,能诱导抗增殖作用和凋亡。 | |||
T18059 |
K-Ras ligand-Linker Conjugate 6
|
Others | Others |
K-Ras ligand-Linker Conjugate 6 is a chemical compound that combines a ligand for K-Ras recruiting moiety and a PROTAC linker. This compound can recruit E3 ligases, including VHL, CRBN, MDM2, and IAP. K-Ras ligand-Linker Conjugate 6 is particularly useful in the synthesis of PROTAC K-Ras Degrader-1, a highly effective K-Ras degrader that achieves ≥70% degradation efficacy in SW1573 cells[1]. | |||
T36246 |
SJF 8240
|
||
c-MET degrader. Comprises MET inhibitor foretinib (GSK 1363089; Cat. No. 6056) joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Degrades c-MET within 6 hours in vitro. Inhibits agonist-driven AKT phosphorylation and GTL16 cell proliferation (IC50 = 66.7 nM). Also degrades exon-14-deleted c-MET in Hs746T cells. | |||
T83947 |
HDAC4 CHDI Degrader 11
|
||
HDAC4 CHDI Degrader 11是一种高效且选择性的HDAC4降解剂(PROTAC),其在Jurkat E6-1细胞和Jurkat细胞中的DC50值分别为4 nM和6 nM。该化合物由类IIa HDAC抑制剂三氟甲基噁二唑通过连接体与Von Hippel-Lindau (VHL) 蛋白的配体连接而成。在亨廷顿病小鼠细胞模型中,HDAC4 CHDI Degrader 11能强效地降解HDAC4(DC50= 1nM)。在神经母细胞瘤细胞系中,可与P-糖蛋白抑制剂Elacridar联用以实现更有效的降解。 |